This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan
by Zacks Equity Research
AstraZeneca's (AZN) PARP inhibitor, Lynparza, receives approval for treating ovarian cancer in Japan, following its label expansion in the United States.
Foreign Stock Roundup: Taiwan Semiconductor Beats, Shell Buys Stake in Silicon Ranch
by Swarup Gupta
Global markets largely echoed Wall Street's fortunes over last week.
Cancer Space Update: Label Expansions, Data Readouts in Focus
by Zacks Equity Research
This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.
Here's Why Nektar Stock Skyrocketed Almost 500% in a Year
by Zacks Equity Research
Nektar's (NKTR) shares soar in a year's time on a robust pipeline including several study initiations, positive readouts and strategic collaborations.
Nektar Boasts Strong Pipeline, Competition Remains a Woe
by Zacks Equity Research
Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.
AstraZeneca's Lynparza Label Now Includes Breast Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.
Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU
by Swarup Gupta
Global markets endured a volatile week, guided by opposing factors.
AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU
by Zacks Equity Research
AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.
Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes
by Zacks Equity Research
Novo Nordisk (NVO) announced that Health Canada has approved Ozempic to improve glycemic control in adults with type II diabetes mellitus.
Pharma Stock Roundup: Allergan Announces Job Cuts, Pfizer Inks Deals
by Arpita Dutt
In a relatively slow week, Allergan's (AGN) job cut announcement remained the key highlight while Pfizer's collaboration agreements with Sangamo and Arvinas were also in focus.
The Zacks Analyst Blog Highlights: Apple, Mastercard, 3M, AstraZeneca and Mondelez
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Mastercard, 3M, AstraZeneca and Mondelez
Can Merck Regain its Mojo in 2018 After an Unimpressive '17?
by Zacks Equity Research
Merck's (MRK) shares declined in 2017 against an increase witnessed by the large-cap pharma industry. It remains to be seen if the company regains momentum in 2018.
The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S
4 Large-Cap Pharma Stocks That Outperformed the S&P This Year
by Zacks Equity Research
We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.
What Drives Juno Therapeutics (JUNO) Above 150% This Year
by Zacks Equity Research
We take a look at the factors especially the focus on CAR-T therapy that led to the phenomenal growth in Juno Therapeutics (JUNO) share price in 2017.
Pharma Stock Roundup: Roche, MNK Announce Acquisition Agreements, Regulatory Updates from Novartis
by Arpita Dutt
Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.
Clovis Up More Than 50% in 2017: What's Driving the Stock?
by Zacks Equity Research
Clovis Oncology (CLVS) stock is rapidly gaining momentum. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.
Cancer Space Update: FDA Approves Label Expansion of 4 Drugs
by Zacks Equity Research
The FDA has approved label expansion of four different drugs from Roche, Exelixis, Pfizer and Bristol-Myers. However, Celgene faced a setback as Revlimid failed in a phase III study.
Why is Nektar (NKTR) Stock Up More Than 350% This Year?
by Zacks Equity Research
Nektar's (NKTR) shares soar in the year so far on a robust pipeline including several study initiations and strategic collaborations.
Pharma Stock Roundup: Aerie's Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs
by Arpita Dutt
This week's pharma sector highlights include the FDA approval of Aerie's (AERI) Rhopressa as well as the label expansion of Pfizer's Bosulif and Bristol-Myers's Opdivo.
Allergan's Vraylar Positive for Bipolar Disease in Phase III
by Zacks Equity Research
Allergan (AGN) releases positive top-line results from a phase III study on Vraylar for treatment of bipolar I depression. The trial meets its primary endpoints with significant progress in patients.
AstraZeneca's Tagrisso Label Expansion Filing Accepted by FDA
by Zacks Equity Research
AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include treatment of NSCLC with EGFR mutation in first-line setting has been accepted by the FDA.
Novo Nordisk's (NVO) Semaglutide Gets Positive CHMP Opinion
by Zacks Equity Research
Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorisation of semaglutide for the treatment of adults with type II diabetes mellitus.
Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study
by Zacks Equity Research
Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.
Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija
by Zacks Equity Research
Acorda (ACOR) resubmits new drug application for its late stage pipeline candidate, Inbrija to the FDA.